Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., . . . de Bono, J. S. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol.
Chicago-стиль цитированияMateo, Joaquin, et al. "Olaparib in Patients With Metastatic Castration-resistant Prostate Cancer With DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-label, Randomised, Phase 2 Trial." Lancet Oncol 2020.
MLA-цитированиеMateo, Joaquin, et al. "Olaparib in Patients With Metastatic Castration-resistant Prostate Cancer With DNA Repair Gene Aberrations (TOPARP-B): A Multicentre, Open-label, Randomised, Phase 2 Trial." Lancet Oncol 2020.